Rotigotine controlled release - Luye Pharma Group

Drug Profile

Rotigotine controlled release - Luye Pharma Group

Alternative Names: LY-03003

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Luye Pharma Group
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Sep 2016 Luye Pharma completes a phase-I trial in Parkinson's disease in USA (NCT02728947)
  • 31 Aug 2016 Luye Pharma plans a phase III trial for Parkinson's disease in USA
  • 01 Aug 2015 Luye Pharma Group completes a phase I trial in Parkinson's disease in USA (NCT02055274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top